Compare Aurora Cannabis Inc (ACB) vs Oscar Health Inc (OSCR) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Oscar Health (OSCR) trades at $31.44, down 2.3% on the day but showing strong technical momentum with a bullish moving average signal. The company reported a significant Q1 2026 earnings beat with EPS of $2.07 versus $1.21 expected, though full-year 2025 results showed a net loss of $443 million. Revenue growth remains robust, projected to increase from $11.7 billion in 2025 to $13.3 billion in 2026, while operating cash flow improved substantially.

The outlook is mixed: strong revenue growth and positive cash flow support upside potential, but persistent net losses and negative ROE pose fundamental risks. Analyst consensus is cautious with a $22.50 price target below current levels, indicating skepticism about sustainability despite recent operational improvements.